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Abstract: In an attempt to achieve post-inhalation self-regulated insulin release, we constructed 
a microparticle agglomerate of nano-sized liposomal particles, with the agglomeration facilitated 
by cross-linkages capable of cleavage by glucose. The particles exhibited a small aerodynamic 
diameter within the human respirable range, but a large geometric diameter that prevents 
macrophage uptake and clearance. Upon intratracheal instillation of the “glucose-sensitive” 
microparticle into the lungs of rats, hyperglycemic events triggered an acceleration of the release 
of insulin achieving normoglycemia shortly after “sensing” the elevated systemic glucose. This 
work is a demonstration of an inhalable particle with long residence times in the lungs capable 
of modulating insulin release based on systemic glucose levels.
Keywords: self-regulated release, inhaled insulin, agglomerated vesicle technology, liposomes, 
glucose sensitive particle
Introduction
A recent long-term (10+ years) study compared an intensive diabetes therapy (involv-
ing 5 or more daily injections or continuous subcutaneous infusion) to conventional 
insulin therapy. The outcome was that a much tighter control of blood glucose levels 
closer to normoglycemia achieved by a more frequent insulin administration beneﬁ  ted 
diabetics, resulting in a signiﬁ  cant reduction in cardiovascular diseases, retinopathies 
and nephropathies (Barnie et al 1999; Nathan et al 2003; Skyler 2004). Therefore, 
there has been an increased effort to develop an insulin delivery system that will mimic 
physiological insulin secretion. To date, there has been some progress in the modula-
tion of insulin delivery based on the blood glucose level (Steil et al 2004; Chu 2005; 
Lapeyre 2006). There has been discussion of coupling of insulin infusion pumps to 
blood-glucose monitoring systems, to enable feedback control of the insulin delivery 
resulting in self-regulated delivery system for insulin. Continuous glucose monitoring, 
however, is problematic (Mastrototaro 2000; Maran et al 2002); shortcomings include 
fouling (Moussy 2002), the need for constant recalibration and the long time constant 
of the sensor (Potts et al 2002).
Two novel triggered-release strategies were proposed in the 1980s, both utilizing 
the blood glucose as the trigger for insulin release from implantable polymeric devices. 
Langer and co-workers designed a polymeric system enzymatically sensitive to glu-
cose (Fischel-Ghodsian et al 1988) while Brownlee et al (1979) proposed a glucose-
sensitive system based on competitive binding. The enzymatically sensitive polymeric 
system consisted of an enzyme (glucose oxidase) which mediates the conversion of 
the marker (glucose) to an acid (gluconic acid). The resulting pH drop can modulate 
the release of insulin utilizing either the pH-dependence of insulin solubility (Brown 
et al 1986, 1996) or pH-responsive polymers (Kost et al 1985; Goldraich et al 1993; 
Traitel et al 2000). The second strategy utilized the competitive binding of glucose 
and glycosylated insulin onto sugar binding moieties. Park and co-workers proposed International Journal of Nanomedicine 2007:2(3) 502
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a copolymer capable of sol-gel phase-reversible transition 
by changes in the environmental glucose concentration 
(Lee et al 1996; Obaidat et al 1996). Once the copolymer 
was exposed to a glucose-binding protein, concanavalin A 
(con A), a gel was formed due to the cross-linking of the 
copolymer’s glucose chains via glucose-con A bridges. 
The hydrogel transitioned to a sol in the presence of free 
glucose. This transition was reversible and once the free 
glucose was removed the sol became a gel again. The insulin 
release exhibited a pulsatile pattern upon stepwise changes 
of glucose (Kim et al 2001). Kim et al proposed glycosyl-
ated insulin molecules complexed to con A (Kim et al 1990, 
1994; Pai et al 1992, 1993). The resulting complex released 
the glycosylated insulin in the presence of glucose, due to 
preferential binding to glucose. In subsequent developments, 
Kim and co-workers have enclosed the complexed species in 
a polymeric membrane pouch that is permeable to glucose 
and glycosylated insulin, but impermeable to con A (Liu 
et al 1997). Use of this technology in vivo requires surgical 
implantation of the pouch in the peritoneal cavity, followed 
by periodic catheter-based reﬁ  ll procedures.
Invasive methods such as these proposed solutions have 
the potential to reduce patient compliance, and noninvasive 
methods are therefore desirable. Among the many alternative 
noninvasive routes (oral, transdermal, and ocular) to deliver 
insulin, the respiratory route has attracted the most attention. 
Insulin has a high permeability through the alveolar mem-
brane (Gannslen et al 1925; Wigley et al 1971) and conse-
quently, the release of free insulin in the region of the alveoli 
is a suitable method to transport signiﬁ  cant amounts of the 
drug into the blood stream (Patton et al 1999). This has led to 
the development of numerous clinical trials of inhaled insulin 
(Patton et al 2004). One of them is close to commercialization 
in US and European Union (Nektar 2006), but is a short-act-
ing inhaled insulin requiring an injection of a long-acting 
insulin to control overnight glycemic episodes. Addressing 
this problem, a breakthrough discovery by Edwards et al 
(1997) in the late 1990’s showed that large porous particles 
with aerodynamic diameter suitable for deep lung delivery, 
but geometric diameter too large for macrophage uptake, can 
facilitate extended release in the lung.
While these advances in pulmonary delivery permit 
controlled release of the drug at some pre-programmed rate, 
there is no possibility of modulating this rate on demand. 
To address this need, we introduced the concept of an AVT 
(Agglomerated Vesicle Technology) particle (Bhavane et al 
2003). The AVT particles consist of liposomes with spacer 
arms on their outer leaﬂ  et, cross linked via the spacers to 
create a chemically cross-linked agglomerate of the con-
stituent liposomes. They are capable of encapsulating drug 
within the constituent vesicles (liposomes), and triggered 
release of drug when exposed to a suitable trigger. These 
particles have been shown to be nebulized from suspension, 
resulting in respirable particles well within the aerodynamic 
diameter range for deep lung delivery, and exhibit minimal 
loss of structure upon nebulization, preserving 70%–85% of 
their contents encapsulated (Bhavane et al 2003). Further, the 
geometric diameter of the particles was shown to be quite 
large (>20 μm) while the structure was shown to be porous 
(Karathanasis et al 2006), resulting in the respirable aero-
dynamic diameter. The triggered release of drug was shown 
to be due to the cleavage of inter-liposome links, with the 
additional possibility of some liposomal membrane disrup-
tion. In a subsequent development (Karathanasis et al 2005), a 
disulﬁ  de linkage capable of cleavage by benign levels of free 
thiols such as cysteine and glutathione was developed. The 
triggered release of ciproﬂ  oxacin from both these particles 
was demonstrated. It was then shown (Karathanasis et al 
2006) that AVT particles with cysteine cleavable links could 
successfully deliver insulin in vivo, when administered to rats 
via the lungs. While the untriggered (basal) release rate could 
maintain normoglycemia in the test animals, hyperglycemic 
events could be controlled by the triggering. Further, in glu-
cose clamp studies at elevated glucose levels where hepatic 
glucose secretion is suppressed, it was shown that systemic 
delivery of insulin was indeed occurring by triggering the 
AVT particles, and that the triggered release persisted for a 
short period of time before subsiding to the basal level.
While the administration of a secondary release agent is 
certainly feasible, it is not as useful as having the release trig-
gered by a product of the disease or condition to be treated. For 
example, if insulin release were to be triggered by the glucose 
level, it would enable a versatile, feedback control system 
for diabetics. In the current work, we have attempted to take 
this platform to the next level, by creating a glucose-sensitive 
linkage that forms the AVT particles. Thus, elevated glucose 
levels trigger insulin release. Fortuitously, the pulmonary 
glucose level appears to correlate with the systemic glucose 
level (Philips et al 2003; Wood et al 2004). Above a systemic 
level of ∼120 mg/dL active transport of glucose via the SGLT 
transporter (Saumon et al 1996) results in a pulmonary level 
of ∼60 mg/dL, which then rises commensurately with the 
systemic level. Intrapulmonary delivery of insulin-containing, 
glucose-sensitive AVT particles therefore has the potential to 
continuously maintain normoglycemia in otherwise hypergly-
cemic subjects. To test this hypothesis, we constructed AVT International Journal of Nanomedicine 2007:2(3) 503
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(3-Dimethylaminopropyl) carbodiimide Hydrochloride (EDC) 
and N-hydroxysulfosuccinimide (sulfo-NHS) were purchased 
from Pierce (Rockford, IL). Insulin USP (human recombinant-
crystalline) was purchased from Serologicals (Milford, MA). 
Ketamine and Xylazine were purchased from Butler Animal 
Health Supply (Richmond, VA). All other materials were 
purchased from Fisher Scientiﬁ  c (Houston, TX).
Synthesis of glycosylated PEG conjugates
Carbodiimide coupling of DSPE-PEG-COOH to galac-
tosamine was performed following a published procedure 
(Hermanson 1996). DSPE-PEG-COOH (200 mg, 0.07 
mmol) was ﬁ  rst micellized in 10 mL of MES buffer at pH 
4.9. EDC (20 mg, 0.1 mmol) was then added and the unstable 
amine reactive intermediate was stabilized using sulfo-
NHS (22 mg, 0.1 mmol). After 15 minutes, galactosamine 
(19 mg, 0.1 mmol) was added. The pH of the mixture was 
increased to 7.3 and maintained for 3 hours. Unreacted EDC, 
sulfo-NHS and galactosamine were removed by dialyzing 
the reaction mixture against PBS at pH 7.3 overnight. The 
suspension was then lyophilized, yielding a white powder. 
Buffer salts and any remaining unreacted sugar were then 
removed by suspending the powder in ethanol at 60 °C, 
ﬁ  ltration of the ethanolic mixture, followed by evaporation. 
TLC in CHCl3/MeOH = 85/15 yielded a single spot with Rf 
= 0.41. The spot of the parent molecule DPSE-PEG-COOH 
was not present. NMR analysis of the ﬁ  nal product was per-
formed on a Bruker Avance 600 MHz NMR Spectrometer, 
with the following results: 1HNMR (DMSO-d6 solvent): 
particles using a Concanavalin A (Con A) linkage to sugars as 
the linker (as in Figure 1). Con A is well known to be highly 
inﬂ  ammatory, and yet has been extensively studied as a pos-
sible component of a glucose sensing device. In fact, triggered 
insulin release systems based on Con A have previously been 
constructed (Lee et al 1996; Kim et al 2001). In our current 
work therefore we used Con A as a representative linker, fully 
recognizing that its long term in vivo use is not advisable, 
yet seeking to demonstrate the feasibility of intrapulmonary 
glucose-sensing systemic insulin delivery. The ability of 
these AVT particles, when administered intrapulmonarily, to 
modulate systemic glucose levels in a rat model was tested. 
Hyperglycemia was induced in the rats by suppressing pan-
creatic activity temporarily using ketamine/xylazine (Abdel 
el Motal et al 1985; Hindlycke et al 1992; Saha et al 2005), 
and simultaneously injecting glucose i.v. To our knowledge, 
this is the ﬁ  rst demonstration of an intrapulmonary, glucose-
sensing, insulin delivery system.
Materials and methods
Materials
1,2-Dipalmitoyl-sn-Glycero-3-Phosphatidylcholine (DPPC) 
and 1,2-Distearoyl-sn-Glycero-3-Phosphatidylethanol-
amine (DSPE) were purchased from Genzyme Pharma-
ceuticals (Cambridge, MA). Cholesterol, concanavalin A, 
D-mannosamine, D-galactosamine, and D-mannosamine 
were purchased from Sigma-Aldrich (St. Louis, MO). DSPE-
PEG-COOH was obtained from Nektar (San Carlos, CA). 
Dithiobis(succinimidylpropionate) (DTSSP), 1-Ethyl-3-
Figure 1 Con A based AVT particles: Liposomes bearing PEG-sugar conjugates on their external surface are agglomerated by free con A.International Journal of Nanomedicine 2007:2(3) 504
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δ 0.9 (t, CH3 of lipid, 6H), 1.3 (m, (CH2)n of lipid, 56H), 
1.6 (m, CH2CH2C = 0, 4H), 2.3 (m, CH2CO, 4H), 2.6 (t, 
CH2CH2CONH, 4H), 3.6 (s, PEG, ∼190H), 3.7–3.8 (over-
lapping sugar and CH2PO4CH2, 9H), 3.9 (t, Gal, 1H), 4.1 (t, 
Gal, 2H), 4.2 (m, Gal, 2H), 4.1–4.2 (m, Gal, 4H), 4.4 (dd, 
Gal, 1H), 5.1 (d, POCH2CHCH2, 1H).
An identical procedure that used glucosamine or man-
nosamine instead of galactosamine was followed to prepare 
the DPSE-PEG-glucose, and DPSE-PEG-mannose conju-
gates respectively.
Preparation and characterization of AVT 
particles
Preparation of core liposomes
Human recombinant insulin was dissolved in citrate buffer 
(100 mM) at pH 2.5. Lipids (56 mole% DPPC, 40 mole% 
Cholesterol, 0.4 mole% DSPE-PEG-NH2 conjugate, 1.2 
mole% each of DSPE-PEG-galactose, DSPE-PEG-glucose, 
and DSPE-PEG-mannose) were dissolved in ethanol at 52 °C 
and hydrated with the insulin solution, the lipid concentration 
in the ﬁ  nal mixture being 50 mM. The suspension was then 
passed 5 times through a 400 nm Nucleopore track-etch mem-
brane at 52 °C and a pressure of approximately 100 psi. MnCl2 
and CaCl2 solutions, which are known to enhance binding of 
sugars to con A, were added to a ﬁ  nal concentration of 3 mM, 
and the overall suspension was made isotonic by the addition 
of NaCl. The liposomal suspension was dialyzed against citrate 
buffer at pH 2.5 for 2 hrs to remove ethanol.
Size determination of liposomes
The size distribution of the liposomes was measured by 
Dynamic Light Scattering (DLS) using a Brookhaven Instru-
ments BI-9000AT Digital Autocorrelator, a BI-200SM goni-
ometer and a Hamamatsu photomultiplier. The light source 
was a 532 nm, Ti-sapphire, frequency doubled laser. For the 
measurement, the liposomal suspension was appropriately 
diluted in citrate buffer. No settling of particles is observed 
in this practically neutrally-buoyant system, and permits 
long data acquisitions.
Preparation of AVT particles
The pH of the liposomal suspension was raised to 6.6, opti-
mal for the cross-linking by Con A. A solution of Con A at 
5 mg/ml in citrate buffer at pH 6.6 in the presence of 1 M 
NaCl, 3 mM CaCl2 and 3 mM MnCl2 and then ﬁ  ltered through 
a 0.8 μm syringe ﬁ  lter in order to remove a small number of 
undissolved Con A aggregates. An aliquot of con A solution, 
sufﬁ  cient to provide 2:1 mole ratio of Con A to glycosyl spe-
cies on the external leaﬂ  et of the liposomes, was added. The 
agglomeration process was complete within 10 min, indicated 
by unchanging size of agglomerates as measured by Fraunhofer 
Diffraction. 30 min after the addition of con A, traces of the 
cross-linker DTSSP reactive towards the amine-PEG were 
added, to create a small number of permanent links between 
the liposomes. The encapsulated fraction was estimated by 
testing an identical preparation where the pH of the liposo-
mal suspension was raised to 5.3, causing external insulin to 
precipitate, followed by extensive dialysis. The insulin was 
estimated by HPLC, after lysis of the agglomerates by ethanol. 
The USP insulin assay (ofﬁ  cial monograph USP 24, 2000) 
was modiﬁ  ed to use a Phenomenex Luna 5 μ C18(2) column 
(150 × 2.0 mm) at a column temperature of 40 °C, ﬂ  ow rate 
0.25 mL/minute; mobile phase acetonitrile: aqueous sodium 
sulfate (28.4 mg/mL) 27:73 v/v and sample injection volume 
20 μL. The AVT insulin preparation was thus estimated to con-
tain a total of 184.9 IU/ml insulin (1 mg ∼ 27.6 IU), of which 
41 IU/ml was encapsulated within the constituent liposomes 
and the remaining was unencapsulated.
Geometric size distribution of AVT particles
The size distribution of the AVT particles was determined 
using Fraunhofer Diffraction Pattern Analysis (Malvern 
Mastersizer with 100 mm lens). The particles were measured 
at different time points in a period of three weeks, and showed 
no change over this period.
Aerodynamic diameter of AVT particles
The aerodynamic diameter of the agglomerated liposomes 
containing insulin was measured by nebulizing 3 ml of the 
liposomal formulation over a period of 10 minutes into an 
Andersen Cascade Impactor (Series 20–800, 1 ACFM non-
viable sampler). A Parijet LC nebulizer was used for the 
cascade impaction studies. The impactor was operated under 
ambient conditions (24 ± 1 °C and ∼55% relative humidity) at 
constant ﬂ  ow rate of 28.3 l/min. These operating conditions 
are consistent with the ofﬁ  cial method described in USP 
(The United States Pharmacopeia, USP 23, NF 18, 1995). 
The ﬁ  lter papers from each plate of the impactor, and the 
ﬁ  lter paper at the end of the last stage were lyophilized. The 
impactor elbow was washed with citrate buffer that was col-
lected and lyophilized. The amount of dry material collected 
on each stage was then assigned to the 50% cutoff size for 
each stage to determine the size distribution. The weight of 
the drug preparation in the nebulizer was recorded before 
and after nebulization in order to complete a mass balance 
calculation and determine any losses upon nebulization. In International Journal of Nanomedicine 2007:2(3) 505
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all cases, over 95% of the initial charge was nebulized and 
collected in the impactor. Mass mean aerodynamic diameter 
was estimated from the measured distribution.
Pharmacodynamic studies in rats
All animal procedures were approved by the Institutional 
Animal Care and Use Committee (IACUC) of the University 
of Texas at Houston. Male Sprague-Dawley rats (Charles 
River Laboratories) weighing 330–350 g were housed in a 
12 hour light /12 hour dark cycle and a constant temperature 
environment of 21 °C. A standard rat diet with water ad libi-
tum was supplied during the 3-day acclimatization period. 
After initial dose-ﬁ  nding studies, 3 groups of 6 rats each were 
used to evaluate the pharmacodynamics of the AVT particles: 
(1) untreated rats with hyperglycemic events (control), 
(2) treated rats with hyperglycemic events, and (3) treated 
rats without hyperglycemic events.
Blood glucose concentration was measured using a Hypo-
guard Assure 3 glucose meter which required 20 μL of blood 
and 10 seconds to provide the reading. The small volume of 
blood required for each reading allowed very frequent sam-
pling (every 5–10 min). Each blood sample was analyzed for 
glucose 2–4 times and the average was recorded.
Upon restraining the rat using a Plexiglas restrainer, it 
was anesthetized with a mixture of ketamine (90 mg/kg) and 
xylazine (10 mg/kg) administered i.p. (at t = −40 min). The 
rat was then placed on a surgical table while temperature was 
maintained stable by placing a temperature-controlled pad 
below the animal. On the establishment of anesthesia indicated 
by the absence of reﬂ  exes, the rat was intratracheally intubated 
via an i.v. catheter (16G × 2 in). The intratracheal tube was 
connected to the ventilator and the rat was under forced ventila-
tion while being still anesthetized. Successful intubation was 
veriﬁ  ed if the chest was expanding with the same rate as the 
frequency of the ventilator. 2.7 μL of AVT particle suspension 
containing 0.5 IU was diluted to 25 μL and then instilled into 
the intratracheal tube while the animal was placed vertically. 
A syringe was then used to push the instilled plug to the end 
of the intratracheal tube, thus insuring instillation at or beyond 
the tracheal bifurcation. The animal was then placed prone on 
the surgical table and the intratracheal tube was connected to 
the ventilator (Harvard model 683, Holliston, MA) operating 
at 2.5 mL tidal volume and 90 strokes/min frequency. Forced 
ventilation was used to ensure the particles’ suspension reached 
into the lungs and was well mixed. After 5 minutes, the forced 
ventilation was terminated and the animal was allowed to 
breathe freely. The duration of the entire process of insertion 
and instillation was ∼10 minutes. 100 minutes after the initial 
cocktail of anesthetic drugs, the animal was injected i.p. once 
more with a cocktail of ketamine (40 mg/kg) and xylazine 
(4 mg/kg). The intratracheal tube was then removed. Blood 
samples were taken from the tail veins under anesthesia or 
restrain to monitor the glucose concentration in the blood. A 
dose of ketamine (50 mg/kg) and xylazine (10 mg/kg) was 
injected i.p. (at t = 90 and 225 min) followed by an injection of 
a glucose solution via the tail vein. The animal was euthanized 
after the end of the 24-hr study by a pentobarbital overdose 
(100 mg/kg) administered i.p. Upon euthanasia, no further 
analysis was performed.
The procedures followed in the case of the untreated (con-
trol) group were similar to the one of the treated animals with 
few modiﬁ  cations. The intratracheal intubation was followed 
by instillation of 25 μL of an isotonic saline solution. The third 
group was similar to the treated group described above with the 
exception of absence of the i.p. injections of anesthetics and 
i.v. injections of glucose solution at t = 90 and 225 min.
Lung histology
Sprague-Dawley rats were anesthetized and intratracheally 
intubated following the procedures described previously. The 
animals were euthanized 24 hrs after intratracheal instillation 
of (1) 20 μl of saline, (2) 40 μl of con A solution containing 
2.4 mg con A/kg body weight, (3) 20 μl of liposomes contain-
ing 0.41 mg of lipids/kg body weight, and (4) 20 μL of AVT 
particles containing 0.41 mg of lipids/kg body weight and 
0.51 mg con A/kg body weight. The dosage of the liposomal 
formulations was chosen based on the pharmacodynamic 
studies. After each animal was euthanized, the lungs were 
gently inﬂ  ated with 10% neutral buffered formalin until 
resistance is appreciated, and then immersed in the formalin 
overnight. The next day, the lungs were serially sectioned 
and submitted for routine histological processing and parafﬁ  n 
embedding. Five micron-thick sections were cut from each 
parafﬁ  n block and placed on glass slides, which were stained 
with a standard hematoxylin-eosin stain. These slides were 
reviewed by a practicing pathologist and evaluated semi-
quantitatively for changes of edema, inﬂ  ammation and other 
histological abnormalities. The inﬂ  ammation triggered by the 
preparations was rank-ordered by the pathologist.
Data analysis
Blood glucose concentrations (pharmacodynamic data) are 
expressed as mean ± SD (Figure 4, n = 3–4). Pharmacody-
namic parameters are expressed also as mean ± SD (Table 1, 
n = 3–4). Each data point was the mean and its standard devia-
tion of the group (3–4 rats per group). Data were compared International Journal of Nanomedicine 2007:2(3) 506
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by variance analysis (Student’s t-test). A p-value less than 
0.05 was used to conﬁ  rm signiﬁ  cant differences at the 95% 
conﬁ  dence level.
Results and discussion
Characterization of AVT particles
Dynamic light scattering measurements of the parent lipo-
somes indicated a diameter of 228 ± 175 nm. This broad size 
distribution is commensurate with the single extrusion ﬁ  lter 
size (0.4 μ). The formation of liposomes with widely distrib-
uted diameters when saturated lipid multilamellar vesicles 
are extruded through such large pore size membranes has 
previously been demonstrated (Sood 1999). Approximately 
23% of the total insulin was found to be encapsulated in 
these liposomes. The theoretical limit of encapsulation can 
be calculated if both a size distribution and a lamellarity dis-
tribution are assumed. The lamellarity was not measured in 
this work, but 23% encapsulation at the diameter of liposomes 
used in this work implies a lamellarity of between one and 
two bilayers per liposome, consistent with that observed in 
previous work on AVT particles (Karathanasis et al 2005). 
Size distributions before and after agglomeration by Con A 
were also measured by Fraunhofer diffraction. The size dis-
tribution of the parent liposomes as measured by Fraunhofer 
diffraction is shown as a solid line in Figure 2. Note that the 
Fraunhofer technique is not accurate in the submicron region, 
and therefore this size distribution is not to be relied on for 
accurate sizing of the parent liposomes, but its presence in the 
submicron range can be taken as an indicator of the presence 
of submicron particles in the sample. After agglomeration by 
the addition of Con A, the size distribution as measured by 
Fraunhofer Diffraction indicated that the agglomerates were 
roughly 23.9 μm ± 22 μm (mean ± SD). This distribution is 
shown in Figure 2 (data plotted as ﬁ  lled diamonds). Interest-
ingly, the distribution shows a peak at 23 μm and a distinct 
shoulder around 6 μm, where the submicron particles have 
completely disappeared. The reasons for this shoulder are 
not clear, but one can speculate that the 6 μm size particles 
constitute an intermediate agglomerate that then participates 
in further agglomeration events as an independent species, and 
results in the formation of larger particles. A similar shoulder 
was also observed in previous preparations of AVT particles 
(Karathanasis 2005), agglomerated by a variety of different 
linkers, over the same time scale. The mechanism of agglom-
eration and the structure of the agglomerates formed is clearly 
dependent on the kinetics of the cross linking steps. Since the 
time scales for agglomeration for each of the particles that 
displayed this shoulder were roughly the same, it suggests that 
their mechanisms were also similar, and thus, similar structures 
also resulted. The encapsulation fraction after agglomeration 
was measured to be 21%, practically equivalent to that before 
agglomeration, suggesting that no signiﬁ  cant leakage of insulin 
occurred during the agglomeration process.
The agglomerates were readily cleaved upon exposure 
to 3 mM free glucose. The size distribution of agglomerates 
10 minutes after addition of the glucose is shown in Figure 2 
(data plotted as ﬁ  lled triangles). It is interesting to note that 
upon glucose-induced cleavage, the agglomerate peak at 
23 μm completely disappears, and a new peak appears at ∼6 
μm, close to the shoulder observed in the agglomerate size dis-
tribution. Further, there is no evidence for the release of parent 
liposomes by glucose-induced cleavage of AVT particles, such 
release would have resulted in the observation of an increased 
number of particles in the submicron range. In previous work 
on AVT particles, we have consistently observed this phe-
nomenon, where the predominant daughter particles formed 
by cleavage of the AVT particles are intermediate clusters, 
and not the parent liposomes. If the speculated agglomeration 
process, with the formation of intermediate size clusters which 
then further agglomerate to form larger particles, is indeed 
occurring, then the formation of these intermediate clusters 
upon cleavage would again be consistent with the cleavage 
of just the most recent bonds formed in the history of a large 
cluster, thus releasing the intermediate clusters. The degree 
of glucose-induced fragmentation of the AVT particle can be 
adjusted by choosing the appropriate types or combination 
of carbohydrates on the liposome. The binding constants of 
Table 1 Pharmacodynamic parameters of the untreated and the treated group during the three glucose excursions
Parameters  Excursion 1  Excursion 2  Excursion 3  Treated  Control  Treated 
(mean ± SD) (t  = 0 ± 90) (t  = 90 ± 195) (t  = 225 ± 325)    
 Control  Treated  Control     
Cmax (mg dL–1) 353  ± 46  320 ± 62  459 ± 27  324 ± 48  525 ± 43  273 ± 39
tmax  (min)  40  0  120 110 255 250
Cbasal (mg dL–1) 145  ± 27  145 ± 27  284 ± 37  98 ± 11  240 ± 7  105 ± 32
AUCe (103 mg dL–1 min)  18.5 ± 4  9.4 ± 2.2  10.4 ± 5.3  7.3 ± 1.5  15.5 ± 5  4.6 ± 3.2International Journal of Nanomedicine 2007:2(3) 507
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con A to a number of glycosyl ligands are available in the 
literature (Mansouri 1983). Ligands that bind far stronger 
than glucose (eg, mannose), as well as weaker than glucose 
(eg, galactose) are known. Therefore, one can ﬁ  ne-tune the 
glucose-sensitivity of the AVT particles by using different 
combinations of ligands. Indeed, we have fabricated a variety 
of AVT particles with a range of numbers and types of sugar-
con A bridges and tested their response to different levels of 
free glucose. We were capable of achieving different size 
reduction rates as well as different resulted sizes ranging from 
small size reduction to complete dissociation to the constituent 
liposomes (Karathanasis 2005).
Nebulization of the AVT particles results in the aerosol-
ization of particles with ∼75% in the respirable range with 
aerodynamic diameter smaller than 5 μm. Figure 3 shows the 
results of cascade impactor measurements of the nebulizate 
from such an experiment. Once again, this data is consistent 
with that observed in past experiments on the nebulization 
of AVT particles. Previous work (Bhavane et al 2003) also 
showed that AVT particles thus nebulized (1) did not sig-
niﬁ  cantly break or lose their structure upon nebulization, 
and (2) did not leak their contents, ie, their encapsulation 
capacity was maintained. Electron microscopy (Karathanasis 
et al 2006) has also conﬁ  rmed the porous nature of AVT 
particles, consistent with their small aerodynamic diameter 
as measured by cascade impaction.
A key question that arises however, is how a nebulized 
(albeit porous) particle can exhibit such a low aerodynamic 
diameter, since one would expect the pores to be ﬁ  lled 
with the aqueous suspending medium, thus resulting in an 
essentially nonporous particle. While there is an obvious 
concern that the nebulization process is fragmenting the AVT 
particle, or somehow selecting the smaller particles alone, 
this is not consistent with the previous observation that the 
size distribution and encapsulation fraction of nebulized AVT 
particles is practically the same as that pre-nebulization. We 
therefore speculate that since the nebulization process and 
cascade impactor measurement, per USP guidelines (The 
United States Pharmacopeia, USP 23, NF 18, 1995), are 
conducted using air at 55% R.H., that much of the aqueous 
medium ﬁ  lling the pores of the AVT particles is evaporating 
prior to entry into the impactor. Such evaporation would then 
result in essentially porous particles entering the impactor, 
exhibiting aerodynamic diameters substantially lower than 
the indicated geometric diameter, and consistent with the 
current measurements. Indeed, in preliminary simulations 
of droplet trajectories and evaporation in nebulizers under 
similar circumstances, we have estimated the evaporation 
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to be sufﬁ  cient to reduce 10+ μm particles to respirable 
diameters. We therefore believe such evaporation is taking 
place in the current experiments, yielding AVT particles 
with aerodynamic diameters in the respirable range <5 μm.
Pharmacodynamic studies in rats
In the rest of the present work, however, in vivo administra-
tion of the AVT particles was accomplished by intratracheal 
instillation. While the predominantly respirable aerodynamic 
diameters of the particles, consistent with past measurements 
of AVT particles, suggests that their inhalation would be fea-
sible, the airﬂ  ow in rats is so different from that in humans that 
the deposition proﬁ  les in rats are not representative of that in 
humans. We therefore chose not to pursue inhaled delivery of 
the AVT particles, but relied on instillation. We recognize that 
instillation causes a somewhat more central-airway weighted 
delivery of drug, rather than the deep lung delivery achievable 
by inhalation. We attempted to reduce this effect by forcing 
ventilation for 5 minutes post instillation, thus forcing distri-
bution of the instilled drug. While this is not very likely to be 
completely equivalent to inhalation in humans, it is highly 
unlikely that the current preparation will be used in humans in 
any case: Con A, the key glucose-sensitive component of the 
current formulation is highly inﬂ  ammatory, and unsuitable for 
human use. We therefore satisﬁ  ed ourselves with aerodynamic 
characterization, which assured us that the particles were 
indeed in the respirable range for humans, and instillation in 
rat lungs as a surrogate for inhalation in humans. The search 
for a replacement for Con A, leading to human-usable glu-
cose-sensitive AVT particles is the subject of ongoing work, 
and a more complete characterization of the glucose-sensitive 
AVT particles with more representative aerosol delivery is the 
subject of future work in this laboratory.
Figure 4 shows the blood levels of glucose resulting 
from the instillation of various preparations to the lungs of 
rats as described. 4 curves are shown in Figure 4, the circles 
representing one animal that had 1 IU of insulin in AVT 
particles administered to its lungs, the triangles representing 
the untreated control (3 animals), and the other two curves 
representing the treated animals with 0.5 IU insulin in AVT 
particles delivered (4 and 3 animals with and without hyper-
glycemic episodes respectively). Initially, upon observing that 
the 1 IU dose caused hypoglycemia in the one test animal, the 
dose was reduced to 0.5 IU for the remaining experiments. 
All animals began (at time zero) with elevated blood glucose 
caused by anesthetic-induced suppression of pancreatic activity 
(Abdel el Motal et al 1985; Hindlycke et al 1992; Saha et al 
2005). Normal glucose levels in this species are ∼100 mg/dL 
(Harkness et al 1995). The untreated control animals exhibited 
continued hyperglycemia (300 mg/dL) for at least the ﬁ  rst 90 
minutes, at which point further anesthesia and an intravenous 
glucose bolus (20 mg) was injected, causing a rapid rise in the 
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blood glucose levels to above 450 mg/dL. This hyperglyce-
mic episode slowly subsided over the next 120 minutes, to a 
level of about 250 mg/dL and appeared to be dropping further 
towards normoglycemic levels (the normoglycemic level of 
100–200 mg/dL for rats is marked by the straight dotted lines 
on Figure 4). At this point, a further dose of anesthesia and a 
glucose bolus (30 mg) caused an even higher increase in the 
blood glucose, to over 500 mg/dL, which was then maintained 
for about one hour before dropping back to around 250 mg/dL. 
On the other hand, the treated animals (with 0.5 IU insulin 
in AVT particles instilled in the lungs) performed much bet-
ter. Their blood glucose level dropped rapidly in the ﬁ  rst 90 
minutes to the low end of the normoglycemic range (without 
dropping into the hypoglycemic range as did the one animal 
with a higher dose of 1 IU). Subsequent doses of anesthetic and 
i.v. bolus glucose (20 mg at 90 minutes, 30 mg at 220 minutes) 
(shown by the ﬁ  lled squares on Figure  4) caused elevations 
in the blood glucose levels, but the peak levels were far lower 
than the untreated control animals, and the elevation also sub-
sided very quickly compared to the untreated controls. Treated 
animals with no subsequent anesthetic or i.v. bolus glucose 
(the ﬁ  lled diamonds on Figure 4) showed no further deviations 
from normoglycemia, and maintained blood glucose levels 
unchanged for the remainder of the 6 hour experiment.
Glucose, therefore, seems to be a suitable marker that 
can be used to trigger the release of insulin from inhaled 
AVT particles, since it appears to be rapidly transported 
into the lungs from the blood. Philips et al (2003) and Wood 
et al (2004) have studied the effect of hyperglycemia on the 
glucose concentration in tracheobronchial lung ﬂ  uids. Their 
study, in volunteer humans, showed: (1) Glucose is not pres-
ent in detectable quantities in the lung ﬂ  uids of non diabetic 
normoglycemic individuals, (2) upon application of blood 
glucose clamps at increasing levels of glucose, no pulmonary 
glucose is observed until the blood levels reach 12–14 mM 
(∼140 mg/dL, the threshold value for a diagnosis of diabetes). 
At this point, the pulmonary glucose level rises rapidly, and 
reaches a level of about 4–5 mM. This led to the conclusion 
that an active transport mechanism for glucose between the 
blood and the lung possibly existed, which is consistent 
0
50
100
150
200
250
300
350
400
450
500
550
0                       30                      60                      90                      120                    150                    180                    210                    240                     270                    300                    330  
B
l
o
o
d
 
G
l
u
c
o
s
e
 
(
m
g
/
d
L
)
Time (min)
Treated group
Treated group in the presence of hyperglycemic events
Untreated animals (Control group)
Treated group with high dose of AVT-insulin
Ket/Xyl (i.p.)
20 mg of Glucose (i.v.)
Ket/Xyl (i.p.)
30 mg of Glucose (i.v.)
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
* *
*
*
*
*
‡ *
‡
‡
‡
‡
‡
*
*
Figure 4 Blood glucose concentration over the period of ~6 hrs of the untreated group (n = 3), treated group with lung instillation of the AVT particle containing 1.4 IU/kg 
(n = 3), and the treated group with lung instillation of the AVT particle containing 1.4 IU/kg followed by hyperglycemic events (n = 4). The asterisk and the double cross 
indicate signiﬁ  cant statistical difference based on two-tailed student’s t-test (p < 0.05, a = 0.05) between the treated group in the presence of hyperglycemic events and the 
control group and between the two treated groups respectively.International Journal of Nanomedicine 2007:2(3) 510
Karathanasis et al
with studies in rats (Saumon et al 1996). In the same study 
Wood et al. (2004) showed that once the threshold for active 
transport is crossed, the transport of glucose is very fast, and 
equilibration takes place in a matter of minutes. Therefore, it 
appears that the transport rate of glucose is sufﬁ  ciently fast to 
allow it to be used as a lung reporter of blood glucose.
Since the AVT preparation contained both unencapsu-
lated (free) and encapsulated insulin, it was expected to have 
short term action, long-term action, and triggered action as 
evidenced in Figure  4. The effects of intratracheally instilled 
free insulin in rats have been studied previously (Hussain et al 
2005, 2006). In both these studies, it was observed that free 
insulin in the rat lung had a very short duration of action, and 
that the duration was dose-dependent. At free insulin doses 
3–5 times higher (1–1.5 IU) than those in our experiments 
(∼0.3 IU) the blood levels of insulin had dropped to normal 
levels after 90 minutes, with corresponding relaxation of 
the blood glucose level as well. At lower doses (0.375 IU) 
comparable to those in our experiment, the blood levels 
of insulin hardly changed, and the glycemic effect relaxed 
extremely quickly, in less than 60 minutes. Thus, the initial 
drop in glycemic levels in our experiments (at times less than 
60 minutes after initiation of therapy) can be attributed to the 
free insulin contribution, while all subsequent effects can be 
attributed to the encapsulated insulin alone.
The effects of i.v. glucose bolus can be quantiﬁ  ed by 
integrating the area under the blood glucose curve, with 
appropriate baselines that isolate the glycemic excursion. The 
results of such integration are shown in Figure 5, showing 
that in each time interval considered, the treated animals had 
far lower glycemic exposure than the untreated animals. This 
is consistent with the hypothesized mechanism of systemic 
glucose being transported into the lung via the SGLT trans-
porter (Saumon 1996), and triggering cleavage of Con A links 
in AVT particles, thus releasing insulin into the lung, which 
in turn is transported into the blood stream and systemically 
distributed, causing a reduction in systemic glucose levels. 
It is also interesting to note that this dose of AVT particles 
did not result in hypoglycemic events, while a larger dose 
did result in hypoglycemia shortly after initial administra-
tion. We hypothesize that at the lower insulin dose, hepatic 
glucose secretion is sufﬁ  cient to restore normoglycemia, in 
the manner that would be normal in an animal with normal 
pancreatic function and insulin secretion.
The remainder of the pharmacodynamic parameters 
extracted from the data in Figures 4 and 5 (Cmax, tmax, Cdelta, 
AUC and Cbasal) are all summarized in Table 1. It is apparent 
that in addition to lowering of the AUC, the basal levels in 
the treated cases are also in the normoglycemic range, and 
the Cmax achieved is similarly reduced. Other parameters are 
not distinguishable within the ranges of statistical variation 
observed in these experiments. We however conclude from 
these data that the level of hyperglycemia induced by glucose 
bolus is signiﬁ  cantly reduced by the treatment with insulin-
containing AVT particles.
Lung histology
AVT particles in their current form however, are not suitable 
for human use. Con A is known to be highly inﬂ  ammatory, 
and cause macrophage activation. In pursuing this work 
however, we hypothesized that the level of Con A we used 
would be very low, substantially below the known toxic 
level (The Registry of Toxic Effects of Chemical Substances 
2006). Further little information is available in the literature 
on the toxicity of Con A upon pulmonary delivery. Since 
automodulation of insulin delivery was demonstrated using 
Con A AVT particles, we decided to examine the possible 
inﬂ  ammatory effects of these particles in the lung. Figure 6 
shows hematoxylin-eosin stained sections of representative 
portions of the lungs of rats treated with (A) Saline (B) Con 
A (C) insulin containing liposomes and (D) AVT particles. 
Clearly, saline treatment had the smallest effect on the lungs, 
with the tissue appearing practically normal, wide open 
alveolar spaces with no sign of inﬂ  ammation. The Con A 
positive control in (B) shows extensive pneumonic changes, 
with mixed inﬂ  ammatory cell inﬁ  ltrates and alveolar hem-
orrhage. Liposome treatment showed patchy lymphocytic 
inﬁ  ltrates in one of the animals (C) but not in the other. AVT 
on the other hand (D) showed the remnants of deposited 
material in the alveoli consistent with the projected long 
residence time of the porous AVT particles in the lung, and 
small signs of inﬂ  ammation as demonstrated by constriction 
of the alveolar spaces. While in an acute treatment, requir-
ing a small number of doses, this response may have been 
acceptable, the long-term effects of a chronic treatment are 
not known and have to be further investigated.
Conclusion
In this work, we have demonstrated what is to our knowledge, the 
ﬁ  rst inhaled insulin delivery system capable of glucose-sensing 
insulin release. The AVT particle constructed in this work uses 
a Con A linkage, binding to sugars, to create a glucose-sensitive 
cleavage mechanism, and is based on 3 previous generation AVT 
particles which had other means of cleavage.
The AVT particles constructed in this work are shown to 
have large geometric diameters with a fairly broad distribu-International Journal of Nanomedicine 2007:2(3) 511
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tion of sizes (∼23.9 ± 22 μ). Cleavage of these particles in 
vitro by the presence of 3mM glucose causes a rapid shift to 
lower particle sizes (6.2 ± 5.8 μ). The aerodynamic diameter 
of the uncleaved AVT particles is substantially lower than 
the geometric diameter, with over 75% of the encapsulated 
insulin being carried by particles in the respirable range of 
5 μ. This is consistent with previous investigations of AVT 
particles, where it has also been shown that nebulization of 
the particles causes minimal loss of encapsulation and change 
in particle structure. We therefore believe that the current 
AVT particles will also be suitable for inhaled drug deliv-
ery. However, the current work only tests their performance 
in a rat model after intratracheal instillation. Future work 
involving nebulization and true aerosol deposition of these 
particles in vivo, and their performance after aerosol delivery 
is required before they can be considered as candidates for 
inhalation delivery of insulin.
The AVT particles after instillation to the lung, however, 
do demonstrate the ability to modulate delivery of insulin 
based on the systemic glucose levels. We hypothesized that 
the systemic glucose levels would be reﬂ  ected in the lung, 
thus enabling cleavage and accelerated release of insulin 
from AVT particles. This has been shown to be the case. 
At post-administration times well beyond the window for 
activity of free insulin in the lung, the AVT particles still 
respond to systemic glucose levels, and the triggered insulin 
release is able to restore normoglycemia rapidly in the test 
animals. A comparison of the glucose pharmacodynamics 
in these test animals to that in untreated control animals 
indicates a substantial improvement in both the AUC and 
Cmax achieved. Lung-instilled AVT thus improves glycemic 
control substantially over the untreated control. At the same 
time, dose adjustment of the AVT prevents the occurrence of 
hypoglycemia. While a high dose of AVT insulin can result 
in hypoglycemia immediately following administration (pos-
sibly because of the free insulin present in the preparation) a 
reduced dose does not do so. More importantly, subsequent 
activations of the AVT particles by systemic glucose bolus 
do not cause any hypoglycemic episodes, while successfully 
controlling the hyperglycemia induced by the bolus.
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AVT particles however, in their current form, may 
cause inﬂ  ammation in the lungs, thus limiting the utility of 
the current preparations. Histological analysis of the lungs 
upon a 24-hr treatment with AVT particles containing con 
A revealed minimal inﬂ  ammation. These were only acute 
studies, however, and the effect of chronic exposure to 
this level of con A will probably not be acceptable. The 
replacement of Con A by a suitable non inﬂ  ammatory, yet 
glucose-binding molecule is the subject of ongoing work. 
Upon identiﬁ  cation of such a molecule, a more complete 
characterization of the aerodynamic behavior, aerosoliza-
tion fate, and inﬂ  ammatory potential of AVT particles is 
indicated. Preliminary indications from this and previous 
work is that the particles will indeed be successful as “smart” 
pulmonary delivery devices.
Figure 6 Histological analysis of hematoxylin-eosin stained lung tissue 24 hrs after treatment (original magniﬁ  cation 100X); (A) In saline-treated animals (n = 2), the lung 
tissue was almost entirely normal, as shown in this view; (B) The con A-treated rats (n = 2) demonstrated extensive pneumonic changes in their lungs. A bronchiole and 
adjacent alveoli show mixed inﬂ  ammatory cell inﬁ  ltrates including neutrophils and lymphocytes, accompanied by alveolar hemorrhage; (C) In liposome-treated animals 
(n = 2), patchy lymphocytic inﬁ  ltrates were noted around a bronchiole, blood vessels, and in the interstitium in the left upper lobe of one of the rats receiving the liposomes; 
(D) In AVT-treated animals (n = 2), alveolar material is focally visible (see arrows) in the lungs, and may represent remnants of the particles (original magniﬁ  cation 100X).
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